Are we even going to launch Tildra?

Quote

anonymous

Guest
The market is going to have bio-similars available and prices are going to be forced down, Our data looks weak compared to the BI compound and Janssen's new psoriasis drug which have much higher efficacy and are way better than Humira in H2H trials, and I'm hearing we may be delayed in filing. And we have a Managed Markets team that has a hard time starting their cars. What's the point?
 






anonymous said:
The market is going to have bio-similars available and prices are going to be forced down, Our data looks weak compared to the BI compound and Janssen's new psoriasis drug which have much higher efficacy and are way better than Humira in H2H trials, and I'm hearing we may be delayed in filing. And we have a Managed Markets team that has a hard time starting their cars. What's the point?
Click to expand...
 












anonymous said:
The market is going to have bio-similars available and prices are going to be forced down, Our data looks weak compared to the BI compound and Janssen's new psoriasis drug which have much higher efficacy and are way better than Humira in H2H trials, and I'm hearing we may be delayed in filing. And we have a Managed Markets team that has a hard time starting their cars. What's the point?
Click to expand...

What is wrong with the Managed Markets team cars?
 






anonymous said:
What is wrong with the Managed Markets team cars?
Click to expand...

It's an American joke to say they can't see set their card. You must be from India

It means they stay at home and don't see any customers. Hahahaha. You get it? They dint out the key in the car and start it and go anywhere

Hahahahaha. You get it

They write up fake reports and say they are doing things but they never leave their house.

Hahahaha you get it.

The cars work fine. The people don't. Hahahaha you get it

It's not their fault the payer companies don't want to talk to price increase companies like Sun with weak rebates and less popular drugs

Hahahaha you get it.
 






Watch the leadership. Once Fabbry, Petrkins, Monzon, Lynch, Patel or Ferguson leaves, that's a clear sign that Tildra is in trouble and the ship is about to hit the iceberg
 












anonymous said:
It hasn't even been submitted to the FDA for final approval. It takes a year from then. Don't hold your breath.
Click to expand...

Last I heard - late Q2 for filing, if even then. We'll be entering a market behind guselkumab and BI 655066, with inferior data. The only thing we'll have in our favor is a different moa. But with the biosims getting a foothold as we speak, it's looking bleak.
 
























Who cares when the drug comes out...it sucks! Early studies show that the efficacy is not that great and many of the doctors involved in the studies are already saying they don't think they would use it when it comes out. And they are saying that not knowing what these geniuses are going to price this shit at.
 
























many clearly don't understand who is currently responsible for Tildra's submission. This is now Merck's drug and they are responsible for filing. Sun takes ownership upon approval. There's a talented team there and they're working hard building a culture and making moves to establish a significant Derm organization with multiple assets across the specialty.
 






anonymous said:
many clearly don't understand who is currently responsible for Tildra's submission. This is now Merck's drug and they are responsible for filing. Sun takes ownership upon approval. There's a talented team there and they're working hard building a culture and making moves to establish a significant Derm organization with multiple assets across the specialty.
Click to expand...

Oh my... The kool aid has kicked in
 






Good luck with that launch...just heard they are looking at about 1 yr from now. By then the market will be so flooded it will get lost in the shuffle and the rest of the company will have to carry it as usual.
 






Top Bottom
Back
Quote